The failure of drug repurposing for COVID-19 as an effect of excessive hypothesis testing and weak mechanistic evidenceArticle Published on 2022-10-182022-11-16 Journal: History and philosophy of the life sciences [Category] COVID19(2023년), SARS, 신약개발, [키워드] agency Analysis applied approval clinical trial Compound conducted COVID COVID-19 EBM+ effective Efficacy Evidence example Excessive hypothesis testing explain false-positive result False-positive results favor Hydroxychloroquine Hypothesis less Mechanistic evidence Medical nihilism. Medicine ongoing trial other diseases Perspective risk second tested therapeutic therapy Treatment treatment for COVID-19 Trial [DOI] 10.1007/s40656-022-00532-9 PMC 바로가기
Dedicated team to ambulatory care for patients with COVID-19 requiring oxygen: Low rate of hospital readmissionResearch article Published on 2022-10-012022-10-05 Journal: International Journal of Infectious Diseases [Category] 치료기술, [키워드] anticoagulation Care consensual COVID-19 determine ED physician emergency department Focusing hospital less Medical organization objective outcome oxygen Oxygen requirement Oxygen therapy Patient patients with COVID-19 Pneumonia prescription readmission Result selected steroid Treatment treatment for COVID-19 [DOI] 10.1016/j.ijid.2022.07.057 [Article Type] Research article
Nafamostat Mesylate for Treatment of COVID-19 in Hospitalised Patients: A Structured, Narrative ReviewArticle Published on 2022-10-012022-11-15 Journal: Clinical pharmacokinetics [Category] COVID19(2023년), SARS, 신약개발, 치료제, [키워드] acute respiratory syndrome addition Antithrombotic Antiviral antiviral potency benefit cell line cellular clinical Clinical outcome clinical study clinical trial clinically Coronavirus-2 COVID-19 disease Disseminated intravascular coagulation drug effective Efficacy enzyme human cells human lung hypothesised indication inhibitory concentration intravenous investigated Japan Laboratory mesylate nafamostat Nafamostat mesylate narrative patients with moderate pharmacokinetic protease recruitment Remdesivir repurposing review robust SARS-CoV-2 serine 2 severe COVID-19 TMPRSS2 transmembrane treatment for COVID-19 viral entry [DOI] 10.1007/s40262-022-01170-x PMC 바로가기
Peimine inhibits variants of SARS-CoV-2 cell entry via blocking the interaction between viral spike protein and ACE2Article Published on 2022-10-012022-11-16 Journal: Journal of food biochemistry [Category] COVID19(2023년), SARS, 변종, [키워드] ACE2 acute respiratory syndrome addition Analysis binding affinity block Calu-3 caused cell entry complementary coronavirus Coronavirus disease 2019 COVID-19 COVID-19 patients docking drug energy transfer evade exhibit Fritillaria functional glycoprotein Hydrogen bond Infection inhibit inhibit SARS-CoV-2 inhibitor Interaction lung cells molecular docking analysis N501Y patients peimine. Protein SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 viral infection significantly small molecule suggested suppresse the spike protein treatment for COVID-19 Vaccine variant variant spike variants of concern variants of SARS-CoV-2 viral entry viral infection viral infections viral spike viral spike protein VoC VOCs [DOI] 10.1111/jfbc.14354 PMC 바로가기
Preclinical findings: The pharmacological targets and molecular mechanisms of ferulic acid treatment for COVID-19 and osteosarcoma via targeting autophagyArticle Published on 2022-09-202022-11-15 Journal: Frontiers in Endocrinology [Category] SARS, 변종, 유전자 메커니즘, 진단, [키워드] 2019 coronavirus disease activities acute respiratory disease applied autophagy Bioinformatics analysis characterized clinical coronavirus COVID-19 deficiency determine develop Effectiveness Evidence ferulic acid Genes impacted individuals MAPK1 mechanism mechanisms medication methodology molecular docking molecular docking analysis molecular mechanism network pharmacology number of infected Ontology osteosarcoma pandemic pathway enrichment Patient Patients with cancer pharmacological pharmacological target PIK3R1 Population potential therapeutic target Preclinical Protein regulatory subunit SARS-CoV-2 STAT3 target targets therapeutic therapeutic targets therapeutic targets. Transcription treat treatment for COVID-19 variant [DOI] 10.3389/fendo.2022.971687 PMC 바로가기
Tetrandrine Treatment May Improve Clinical Outcome in Patients with COVID-19Article Published on 2022-09-012022-11-15 Journal: Medicina [Category] SARS, 치료제, [키워드] antibiotic Antibiotics association China Chinese clinical Clinical outcome collected cough COVID-19 COVID-19 pandemic COVID-19 patient defined diagnosis of COVID-19 effective Effectiveness Factor fatigue group IMPROVE indicated material Medicine Mild moderate natural antiviral patients SARS-CoV-2 significant difference tetrandrine traditional Chinese medicine. treat treating COVID-19 Treatment treatment for COVID-19 were assessed with COVID-19 [DOI] 10.3390/medicina58091194 PMC 바로가기
Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLLArticle Published on 2022-08-262022-11-15 Journal: Journal of Hematology & Oncology [Category] SARS, 진단, [키워드] 95%CI Admission advanced age affected age albumin Analysis anticoagulation therapy bleeding C-reactive protein CLL Complication conducted COVID-19 COVID-19 diagnosis D-dimer Data collection death deficiency defined development dose administration ENhance European event high risk Hospitalization Hospitalized ICU immune increased risk initiative leukemia LMWH Most patient multivariate model nasal Occurrence outcomes oxygen oxygen supplementation Patient peak D-dimer pharyngeal polymerase chain presence of comorbidities Prognostic factor prophylactic dose Protective receiving recommendation reported Retrospective multicenter study risk RT-PCR SARS-CoV-2 severe COVID-19 severity STROBE susceptible swabs the disease Thromboembolic event Thromboprophylaxis thrombosis thrombosis. Thrombotic events Treatment treatment for COVID-19 were used [DOI] 10.1186/s13045-022-01333-0 PMC 바로가기
Inhaled therapy for COVID-19: Considerations of drugs, formulations and devicesCOVID-19에 대한 흡입 요법: 약물, 제형 및 장치에 대한 고려 사항Review Published on 2022-08-252022-09-11 Journal: International journal of pharmaceutics [Category] COVID19(2023년), SARS, 변종, 신약개발, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus Administered administration anti-SARS-CoV-2 antiviral drug antiviral drugs Antiviral treatment approach Clinical studies Combinational Concentration coronavirus COVID-19 COVID-19 pandemic Device disease dose drug drug combination drug susceptibility drugs effective effective vaccine Efficacy etiological agent include Infection inhalation Inhaled intravenous key consideration limitations lower dose lung majority mono potency preclinical studies reduce reduced responsible SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 shown Side effects tested therapy Treatment treatment for COVID-19 Treatment. [DOI] 10.1016/j.ijpharm.2022.122042 PMC 바로가기 [Article Type] Review
Elevated Myl9 reflects the Myl9-containing microthrombi in SARS-CoV-2-induced lung exudative vasculitis and predicts COVID-19 severity상승된 Myl9는 SARS-CoV-2 유발 폐삼출성 혈관염에서 Myl9 함유 미세혈전을 반영하고 COVID-19 중증도를 예측합니다Article Published on 2022-08-162022-09-12 Journal: Proceedings of the National Academy of Sciences of [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] accompanied accumulated activation of platelets acute respiratory syndrome analysis Autopsy Clinical severity coronavirus coronavirus disease correlated COVID-19 COVID-19 patient COVID-19 severity exudative vasculitis fatal disease histological immune dysregulation immunothrombosis lung marker Microscopy microthrombi monocyte mononuclear cell Mortality nonconventional monocytes Pathogenesis pathology Peripheral blood plasma plasma Myl9. predict provide reflect SARS-CoV-2 severity Single-cell RNA sequencing the disease treatment for COVID-19 Vascular Vasculitis vessels X-ray spectroscopy [DOI] 10.1073/pnas.2203437119 PMC 바로가기 [Article Type] Article
Nanoformulated Remdesivir with Extremely Low Content of Poly(2-oxazoline)-Based Stabilizer for Aerosol Treatment of COVID-19COVID-19의 에어로졸 치료를 위한 폴리(2-옥사졸린) 기반 안정제 함량이 매우 낮은 나노제형 렘데시비르Article Published on 2022-08-012022-09-11 Journal: Macromolecular bioscience [Category] COVID19(2023년), SARS, 치료제, [키워드] 2-Oxazoline aerosol antiviral efficacy antiviral therapy approved can be used cause Characteristics clinically Concentration content COVID-19 Diseases dose global pandemic IMPROVE Infection nanocrystal outcome pandemic physician poly(2-oxazoline) Polymer reagent Remdesivir remdesivir. SARS-CoV2 Stabilizer Suspension target the disease therapeutic treat treatment for COVID-19 virus [DOI] 10.1002/mabi.202200056 PMC 바로가기 [Article Type] Article